Abstract:e14662 Background: Immune checkpoint inhibitor (ICI) combined with anti-angiogenic therapy is the standard first-line treatment for unresectable HCC patients. However, most patients do not derive durable benefit and will progress faster. Simultaneously, sufficient clinically validated biomarkers to stratify patients are lacking in HCC. Recent studies have shed a light on the strong connection between immunotherapy efficacy and tumor immune microenvironment (TIME) in HCC. Thus, this study aims to investigate TIME features before treatment to develop a potential way for survival prediction which may optimize risk stratification. Methods: A total of 84 unresectable HCC patients who received first-line ICI plus anti-angiogenic therapy at Nanjing Drum Tower Hospital were included. 4 multiplex immunohistochemistry (mIHC) panels containing 18 biomarkers were developed to thoroughly evaluate immune cells in TIME before therapy, such as cytotoxic T cells, tissue-resident memory T cells, macrophages and neutrophils. TIME features were then extracted from raw image by digital pathology, including cell subpopulation abundance and spatial profiling. We identified a list of TIME features associated with objective response rate (ORR), progression free survival (PFS) and overall survival (OS), and developed a TIME-based risk score (TIS) in our cohort using machine-learning. Results: After data cleaning, a total of 78 patients with complete clinical information and TIME features were included and split into training and validation sets. A higher positive rate of CD103+ cells and CD8+ cells were observed in responder, while patients with higher CD66b+ positive rate showed shorter PFS and OS. In terms of spatial profiling, tumor cells accompanied with more CD8+ cells were associated with longer PFS and OS, while longer distance from CD14+ cells and CD66b+ cells to tumor cells favored longer PFS and OS. Regarding PFS prediction, our machine-learning model TIS included both immune cell abundance and spatial features. Stratifying patients in the low- and high-risk groups using TIS revealed prolonged PFS (p<0.0001, HR: 0.24, 95%CI [0.13-0.45]) and OS (p = 0.00057, HR: 0.27, 95%CI [0.12-0.60]) in TIS low-risk group. Moreover, ORR in TIS low-risk group was 52.9% (17/34) and 15.9% (7/44) in TIS high-risk group. Univariable and multivariable analysis demonstrated that TIS was an independent predictor for ORR (p = 0.0017), PFS (p = 0.00065) and OS (p = 0.00042). Independent validation is still awaited. Conclusions: This study demonstrates that our machine-learning based risk score can improve treatment response and survival prediction using TIME features, which provides the potential to optimize risk stratification before first-line treatment for unresectable HCC patients.

Evaluation of homologous recombination deficiency (HRD) score and immuno-tumor microenvironment (iTME) as biomarkers of soft tissue sarcoma (STS) survival and response to immune checkpoint inhibitor therapy.

Correlative Study on the Relationship Between the Expression of M6a-Related Genes and the Prognosis and Immunotherapy of Soft Tissue Sarcoma.

Comprehensive profiling of immune-related genes in soft tissue sarcoma patients

The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy

Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor.

Potential Use of Homologous Recombination Deficiency Score As an Indicator of Therapy Selection in Leiomyosarcoma Patients.

Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy

Pathological Evaluation of Tumor Immune Microenvironment Before First-Line Anti-Pd1 Plus Anti-Angiogenic Therapy in Patients with Unresectable Hepatocellular Carcinoma (HCC): Towards a Prediction for Treatment Efficacy.

Pan-cancer Analysis Reveals Homologous Recombination Deficiency Score As a Predictive Marker for Immunotherapy Responders

1654P Analysis of Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Several Subtypes of Sarcomas

Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced esophageal cancer.

Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma

Characterization Of Immune-Related Long Non-Coding Rnas To Construct A Novel Signature And Predict The Prognosis And Immune Landscape Of Soft Tissue Sarcoma

TMErisk score: A tumor microenvironment-based model for predicting prognosis and immunotherapy in patients with head and neck squamous cell carcinoma

Tumor microenvironment evaluation to predict anti–PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.

Identification of a Tumor Microenvironment-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Colon Cancer

Intratumoral NKp46+ natural killer cells are spatially distanced from T and MHC-I+ cells with prognostic implications in soft tissue sarcoma

Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patients